-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the announcement, the first time health yuan submitted for inhalation with isopropyl bromide solution registration was accepted on March 12, 2019, the acceptance number is CYHS1900195, CYHS1900196.
this product can be used in β with inhalation-persetressor agitants to treat reversible gas vessel obstruction caused by acute or chronic asthma.
products for the company's independent research and development products.
Isopropropyl Bromide is an anticholinelic energy drug with strong bronchial smooth muscle relaxation, which can significantly improve lung function and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD), relieve the symptoms of breathing difficulties, improve sleep and quality of life, and is one of the main drugs for COPD treatment.
isopropyl propylene bromide in β inhaled and imported chemicals, and is widely used to treat acute asthma attacks.
, the cumulative direct investment of health yuan into the inhalation of ammonium isopropyl bromide solution research and development costs of about 11.8698 million yuan.
it is understood that the solution of ammonium isopropyl bromide for inhalation was first developed by Boehringer-Ingelheim, which was approved for listing in the UK in August 1986 and entered the Chinese market in 2004.
IQVIA sampling statistics estimate data, the domestic inhalation of isopropyl tobly bromide solution in 2019 end-sales amount of about 501 million yuan.
According to the website of the Drug Review Center of the State Drug Administration and the Xianda database, up to now, a total of 6 domestic manufacturers (including the Company and 1 import registration) declared, Health Yuan is the first domestic according to the new registration classification application and approved 4 classes of generic drugs manufacturers.
source: Health Meta Bulletin.